Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy

Trial Profile

A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Capecitabine (Primary) ; Varlitinib (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.
    • 08 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Mar 2020.
    • 21 Sep 2018 According to an ASLAN Pharmaceuticals media release, data from this study will be presented at the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top